Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25689233 | 0.90 | SMN1; SMN2 (0.50) | SMN1; SMN2HSD11B1HTT | |
| SCHEMBL25561912 | 0.85 | SMN1; SMN2 (0.61) | SMN1; SMN2HSD11B1EPHX1EPHX2RECQL | |
| SCHEMBL26138774 | 0.82 | SMN1; SMN2 (0.40) | SMN1; SMN2HSD11B1 | |
| SCHEMBL27022615 | 0.79 | SMN1; SMN2 (0.46) | SMN1; SMN2PKM | |
| SCHEMBL22677527 | 0.79 | KCNH2 (0.56) | — | |
| SCHEMBL27812858 | 0.79 | SMN1; SMN2 (0.69) | SMN1; SMN2HSD11B1EPHX1EPHX2RECQL | |
| SCHEMBL21099934 | 0.78 | SMN1; SMN2 (0.37) | SMN1; SMN2 | |
| SCHEMBL12798281 | 0.78 | BCHE (0.44) | SMN1; SMN2HSD11B1 | |
| SCHEMBL16886298 | 0.77 | EPHX2 (0.46) | EPHX1EPHX2GAA | |
| SCHEMBL12156678 | 0.77 | SMN1; SMN2 (0.67) | SMN1; SMN2HSD11B1EPHX1EPHX2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11364300-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2022-06-21 | — | — | US | disclosed |
| US-20210338824-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-11-04 | — | — | US | disclosed |
| US-8809337-B2 | Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-08-19 | — | — | US | disclosed |
| US-8809337-B2 | Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-08-19 | — | — | US | disclosed |
| US-20130203770-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-08-08 | — | — | US | disclosed |
| US-20130203770-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-08-08 | — | — | US | disclosed |
| US-20110118278-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-19 | — | — | US | disclosed |
| US-7897765-B2 | Therapeutic compounds and uses thereof | ELIXIR PHARMACEUTICALS, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090264410-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | ELIXIR PHARMACEUTICALS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-7504506-B2 | Therapeutic compounds and uses thereof | ELIXIR PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264410-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GHSR, GHRHR, GPR119 | SMN1; SMN2 3366/4885HSD11B1 197/4885EPHX1 3202/4885 |
| US-20210338824-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | SMN1; SMN2 2014/4885HSD11B1 2929/4885EPHX1 4779/4885 |
| US-11364300-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | SMN1; SMN2 2014/4885HSD11B1 2929/4885EPHX1 4779/4885 |
| US-20130203770-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | DMPK, DCK, MAP3K19 | SMN1; SMN2 4039/4885HSD11B1 3602/4885EPHX1 3408/4885 |
| US-20110118278-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | DMPK, DCK, MAP3K19 | SMN1; SMN2 4039/4885HSD11B1 3602/4885EPHX1 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.